Evogene Ltd.EVGN
Market cap
P/E ratio
| Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Revenue | 3 | 2 | 1 | 1 | 1 | 2 | 6 | 9 |
| Cost of revenues | 3 | 1 | 0 | 1 | 1 | 1 | 2 | 3 |
| Gross profit | 1 | 0 | 0 | 0 | 0 | 1 | 4 | 6 |
| Research and development, net | 17 | 15 | 16 | 17 | 21 | 21 | 21 | 17 |
| Sales and marketing | - | - | - | - | - | 4 | 4 | 3 |
| General and administrative | 4 | 4 | 4 | 5 | 7 | 6 | 6 | 7 |
| Other expenses (income) | - | - | - | - | - | 4 | - | -1 |
| Total operating expenses, net | 22 | 20 | 22 | 25 | 31 | 28 | 30 | 28 |
| Operating loss | -22 | -20 | -21 | -25 | -31 | -27 | -27 | -22 |
| Finance income | 2 | 1 | 3 | 2 | 2 | 1 | 1 | 8 |
| Financing expenses | 1 | 2 | 1 | 3 | 1 | 3 | 1 | 3 |
| Financing income (expenses), net | - | - | - | - | - | - | 1 | 4 |
| Share of loss of an associate | - | - | - | - | - | - | - | -0 |
| Loss before taxes on income | -21 | -21 | -19 | -26 | -30 | -30 | -26 | -18 |
| Taxes on income | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Loss | -21 | -21 | -19 | -26 | -30 | -30 | -26 | -18 |
| Equity holders of the Company | - | -21 | -18 | -23 | -28 | -27 | -24 | -16 |
| Non-controlling interests | - | -0 | -1 | -3 | -3 | -3 | -2 | -2 |
| Loss | -21 | -21 | -19 | -26 | -30 | -30 | -26 | -18 |
| Basic earnings (loss) per share | - | - | - | - | - | -0.65 | -0.52 | -2.89 |
| Diluted earnings (loss) per share | - | - | - | - | - | -0.65 | -0.52 | -2.89 |